{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:17Z","timestamp":1792979897238,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Antiretroviral therapy (ART) based on dolutegravir (DTG) has emerged as a critical component in the treatment of HIV infection and is widely utilized in clinical practice. However, the existing post-marketing pharmacovigilance studies on DTG are incomplete; therefore, this study aims to comprehensively analyze the adverse events (AEs) related to DTG by utilizing the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study includes adverse event reports from the fourth quarter of 2013 to the fourth quarter of 2024 in the FAERS database. Four disproportionality analysis methods were employed for adverse event signal mining: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). Additionally, clinical priority and time-to-onset characteristics were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13,007 case reports were collected with DTG as the primary suspected (PS) drug, including 32,383 AEs. Observed disproportionate associations with the use of DTG were related to pregnancy, puerperium and perinatal conditions (<jats:italic>n<\/jats:italic> = 688; ROR = 5.53, 95% CI 5.13\u20135.96), hepatobiliary disorders (<jats:italic>n<\/jats:italic> = 655; ROR = 2.45, 95% CI 2.27\u20132.65), and congenital, familial and genetic disorders (<jats:italic>n<\/jats:italic> = 550; ROR = 6.11, 95% CI 5.62\u20136.65). A total of 341 AE signals were identified in the overall analysis, among which 164 were rated as moderate clinical priority, with no high clinical priority signals. Notably, subgroup analyses revealed that progressive multifocal leukoencephalopathy (<jats:italic>n<\/jats:italic> = 9) in males, progressive multifocal leukoencephalopathy (<jats:italic>n<\/jats:italic> = 6) and deafness neurosensory (<jats:italic>n<\/jats:italic> = 3) in the 18\u201345 age group, and hepatic necrosis (<jats:italic>n<\/jats:italic> = 4) in the 46\u201365 age group were rated as high clinical priority. The overall onset time for all AEs exhibited an early failure pattern, with a median onset time of 74\u00a0days (IQR 19\u2013310.5), whereas the median onset time for designated medical events (DMEs) was 59\u00a0days (IQR 12\u2013186).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The long-term safety of DTG requires reassessing its risk-benefit ratio. To mitigate the risk of irreversible organic damage, a structured risk management strategy is essential. This strategy should encompass restrictions on contraindicated populations, enhanced monitoring of high-risk subgroups, and the implementation of post-marketing prospective cohort studies to ensure the sustainability of antiviral therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1625601","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:39Z","timestamp":1753853499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B2","unstructured":"2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/QAD.0000000000003020","article-title":"The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide\/emtricitabine\/dolutegravir, tenofovir disoproxil fumarate\/emtricitabine\/dolutegravir or tenofovir disoproxil fumarate\/emtricitabine\/efavirenz","volume":"35","author":"Asif","year":"2021","journal-title":"AIDS"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/QAD.0000000000002289","article-title":"The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid","volume":"33","author":"Cabrera","year":"2019","journal-title":"AIDS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"B8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12888-025-06820-5","article-title":"Patients reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy real-life clinical practice in Ethiopia: multi center crossetional study","volume":"25","author":"Chanie","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"ofx122","DOI":"10.1093\/ofid\/ofx122","article-title":"Abacavir\/Dolutegravir\/Lamivudine (Triumeq)\u2013induced liver toxicity in a human immunodeficiency virus\u2013infected patient","volume":"4","author":"Christensen","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2352-3018(24)00294-7","article-title":"Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial","volume":"12","author":"Cordova","year":"2025","journal-title":"Lancet HIV"},{"key":"B13","doi-asserted-by":"publisher","first-page":"ofae752","DOI":"10.1093\/ofid\/ofae752","article-title":"Preswitch regimens associated with weight gain among persons with HIV who switch to integrase inhibitor-containing regimens","volume":"12","author":"Cutshaw","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"B14","unstructured":"2025"},{"key":"B15","volume-title":"Drugs and lactation database (LactMed\u00ae)","year":"2006"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2352-3018(23)00141-8","article-title":"Metabolic implications and safety of dolutegravir use in pregnancy","volume":"10","author":"Dontsova","year":"2023","journal-title":"Lancet HIV"},{"key":"B17","unstructured":"EACS Guidelines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12874-025-02498-1","article-title":"A systematic review of mediation analysis frameworks in studies examining the determinants of cardiometabolic outcomes in people living with HIV","volume":"25","author":"Ebasone","year":"2025","journal-title":"BMC Med. Res. Methodol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJMra2212877","article-title":"Antiretroviral therapy and adverse pregnancy outcomes in people living with HIV","volume":"388","author":"Eke","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1113032","DOI":"10.3389\/ftox.2023.1113032","article-title":"Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors","volume":"5","author":"Foster","year":"2023","journal-title":"Front. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","article-title":"Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review","volume":"8","author":"Fournier","year":"2017","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1175917","DOI":"10.3389\/fcell.2023.1175917","article-title":"Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir","volume":"11","author":"Gelineau-van Waes","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofad441","DOI":"10.1093\/ofid\/ofad441","article-title":"Strengthening the evidence: similar rates of neural tube defects among deliveries regardless of maternal HIV status and dolutegravir exposure in hospital birth surveillance in Eswatini","volume":"10","author":"Gill","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"B25","unstructured":"2025"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz","volume":"73","author":"Griesel","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1509561","DOI":"10.3389\/fphar.2025.1509561","article-title":"Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/QAD.0000000000004032","article-title":"Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV","volume":"39","author":"Hey","year":"2025","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors","volume":"21","author":"Hoffmann","year":"2019","journal-title":"AIDS Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"20503121241260613","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"Jemal","year":"2024","journal-title":"SAGE Open Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10600280251324337","DOI":"10.1177\/10600280251324337","article-title":"Comparison of error incidence between single-tablet versus multiple-tablet INSTI-based regimens in the inpatient setting","author":"Kelley","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(23)00108-X","article-title":"Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study","volume":"10","author":"Kourtis","year":"2023","journal-title":"Lancet HIV"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1111\/bcp.15683","article-title":"Pharmacokinetic and pharmacokinetic\/pharmacodynamic characterization of the dolutegravir\/rilpivirine two-drug regimen in SWORD-1\/-2 phase 3 studies","volume":"89","author":"Mehta","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/biology12040580","article-title":"Antiretrovirals promote metabolic syndrome through mitochondrial stress and dysfunction: an in vitro study","volume":"12","author":"Mohan","year":"2023","journal-title":"Biol. (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAI.0000000000003101","article-title":"Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide","volume":"92","author":"Palella","year":"2023","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"P\u00e9rez-Valero","year":"2023","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/jac\/dkad187","article-title":"Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study","volume":"78","author":"Pr\u00e9ta","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"23259582241311912","DOI":"10.1177\/23259582241311912","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people living with HIV attending centre of excellence in HIV care at a tertiary level teaching hospital in north India\u2014a pilot study","volume":"24","author":"Ram","year":"2025","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1247","DOI":"10.1002\/prp2.1247","article-title":"Integrase inhibitor drugs during pregnancy and congenital anomalies: a case\/non-case study from the global pharmacovigilance database VigiBase\u00ae","volume":"12","author":"Saint-Lary","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e234483","DOI":"10.1136\/bcr-2020-234483","article-title":"Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis","volume":"13","author":"Simeni Njonnou","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B46","volume-title":"HIV and AIDS, in StatPearls","author":"Swinkels","year":"2024"},{"key":"B47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/QAD.0000000000000542","article-title":"Acute pancreatitis associated with dolutegravir and lamivudine\/abacavir administration","volume":"29","author":"Thompson","year":"2015","journal-title":"AIDS"},{"key":"B49","doi-asserted-by":"publisher","first-page":"ofae139","DOI":"10.1093\/ofid\/ofae139","article-title":"Sex-based disparities in the transition to dolutegravir-based antiretroviral therapy in west African HIV cohorts","volume":"11","author":"Tiendrebeogo","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"B50","unstructured":"2025"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","article-title":"Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy","volume":"70","author":"van De Ven","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B53","unstructured":"Adult and Adolescent ARV HIV Clinical Guidelines | NIH\n          \n          \n          2024"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2352-3018(24)00155-3","article-title":"Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial","volume":"12","author":"White","year":"2025","journal-title":"Lancet HIV"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.eclinm.2019.11.003","article-title":"Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy","volume":"17","author":"Wijting","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/FPC.0000000000000515","article-title":"Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens","volume":"34","author":"Wu","year":"2024","journal-title":"Pharmacogenet Genomics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1625601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:45Z","timestamp":1753853505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1625601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":59,"alternative-id":["10.3389\/fphar.2025.1625601"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1625601","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1625601"}}